While some compounding pharmacies have stopped making alternatives to Wegovy and Zepbound since shortages were declared over, ...

As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Chicago, IL – June 16, 2025 – Zacks.com releases the list of companies likely to issue earnings surprises. This week’s list ...

Investing in today’s dynamic market requires a keen eye for value, and Hims & Hers Health, Inc. ($HIMS) has been catching attention with its explosive ...

Discover why Hims & Hers is leading the telehealth market with strong growth, a loyal user base, and expansion into new ...

Salem Investment Counselors Inc. bought a new stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look ...

Eli Lilly found itself in a pharmaceutical pickle after its CFO claimed telehealth partners don’t compound key weight-loss ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has cemented its position as a leading ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

Eli Lilly will partner only with telehealth firms that agree to stop selling compound versions of its drug Zepbound or Novo Nordisk’s Wegovy, a move that sidelines Hims & Hers Health, Bloomberg ...

Whether you want a medicated solution or an all-natural fix, these pro-backed recommendations can start helping in as little ...